Highlights Biocon Limited

Equities

BIOCON

INE376G01013

Market Closed - NSE India S.E. Other stock markets 07:43:51 2024-06-10 am EDT			5-day change	1st Jan Change
339.9 ^INR	+1.16%		+9.91%	+36.15%

Jun. 07	AbbVie's tight grip on Humira market raises concerns about biosimilars	RE
Jun. 03	Biocon Limited Receives Approval from the U.S. Food and Drug Administration	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocon Limited Receives Approval from the U.S. Food and Drug Administration	Jun. 03	CI
Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	May. 24	MT
Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	May. 23	CI
Biocon's Consolidated Net Profit Declines in Fiscal Q4	May. 17	MT
India's Biocon posts Q4 profit fall as higher raw material costs bite	May. 16	RE
Biocon Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024	May. 16	CI
Biocon Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 16	CI
Biocon Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 16	CI
Biocon Signs Deal with Medix for Commercialization of Chronic Weight Management Drug in Mexico	May. 13	MT
Biocon Limited Signs Semi-Exclusive Distribution and Supply Deal for the Commercialization of Generic Saxenda® (Liraglutide) in Mexico with Medix	May. 12	CI
Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	Apr. 20	CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	Apr. 17	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	Apr. 17	CI
Biocon Board to Consider Dividend for Fiscal 2024	Apr. 10	MT
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	Apr. 02	MT
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	Mar. 31	CI
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	Mar. 27	CI
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	Mar. 15	MT
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	Mar. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biocon Limited

Equities

BIOCON

INE376G01013

Highlights

Filters